If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
TsrM in thiostrepton biosynthesis PoyD and PoyC in polytheonamide biosynthesis TbtI in thiomuracin biosynthesis NosN in nosiheptide biosynthesis EpeE (previously called YydG) in epipeptide biosynthesis MoaA in molybdopterin biosynthesis PqqE in pyrroloquinoline quinone biosynthesis TunB in tunicamycin biosynthesis OxsB in oxetanocin biosynthesis BchE in anaerobic bacteriochlorophyll biosynthesis F0 synthases in F420 cofactor biosynthesis MqnE and MqnC in menaquinone biosynthesis QhpD in post-translational processing of quinohemoprotein amine dehydrogenase RumMC2 in ruminococcin C biosynthesis
Once the columns are filled with stationary phase, the mobile phase is pumped through, not continuously but, in pulses. The solvent motion created by a pulsed pumping action creates the mixing and settling that is common to most all forms of countercurrent chromatography.
Slovakia: Prime Minister Robert Fico criticized the actions of the United States, stating that "International law does not apply, military power is used without the mandate of the UN Security Council, and everyone who is great and strong does what he wants to promote their own interests," and that "I resolutely reject such a disruption of international law, as I did in the Iraq war, in the denial of Kosovo as a sovereign state, or in the use of Russian military power in Ukraine." He also suggested that the European Union should apply the same standards that were used with Russia when it invaded Ukraine, saying that "Either the use of American military force in Venezuela will be condemned and be consistent with attitudes to the war in Ukraine, or, as usual, remain pharisaical." Spain: The Foreign Ministry called for "de-escalation and moderation", and for compliance with "international law and the principles of the UN charter" adding that the ministry was "prepared to offer its good offices to achieve a peaceful and negotiated solution". They reiterated that they did not recognize the results of the 2024 Venezuelan presidential election and that Spain "has welcomed, and will continue to welcome, tens of thousands of Venezuelans who have had to leave their country for political reasons." On 4 January 2026, Brazil, Spain, Chile, Colombia, Mexico, and Uruguay issued a joint statement to express their "profound concern and firm rejection of the military actions carried out unilaterally in Venezuelan territory" by the United States.
Sources: en.wikipedia.org
=== Packages === Tetra Classic is the name of the first, tetrahedral package, launched by Tetra Pak in 1952, with an aseptic version released in 1961 and still in use, mainly for portion-sized cream packages and children's juices. The Tetra Brik, a package in the shape of a rectangular cuboid, was launched in 1963 after a long and costly development process. An aseptic version, Tetra Brik Aseptic was launched in 1969. In terms of entities sold, it is the most popular of the Tetra Pak packages. The pillow-shaped Tetra Fino Aseptic was introduced in 1997, aiming to provide low cost and simplicity. Tetra Gemina Aseptic was introduced in 2007 as the "world’s first roll-fed gable top package with full aseptic performance". The Tetra Prisma Aseptic was launched in 1996. It has an octagonal shape with the aim of providing a more ergonomic experience. The Tetra Rex is a cuboid shaped package with a gable-top. It was launched in Sweden in 1966. Tetra Recart was launched in 2003 and is a package shaped as a rectangular cuboid that is meant to provide an alternative to previously canned foodstuffs such as vegetables, fruit and pet food. Tetra Top was launched in 1986 as a re-closable, rounded cuboid package with a plastic upper part, including opening and closure elements. The lid, molded in polyethylene in a single mold, makes it easy to open and reclose. Tetra Wedge Aseptic was developed to keep packaging material to a minimum while retaining a square surface underneath. It was introduced in 1997.
The small council decided to disregard Viserys' declaration of Rhaenyra as his heir, and conspired to crown Prince Aegon (Viserys' eldest son) as the next king of Westeros. Their precedent to justify Aegon's ascension was the Great Council of 101 AC, where Viserys was chosen over Princess Rhaenys on account of sex. His death was finally revealed to the public a week later, when the silent sisters prepared his body for a cremation ceremony traditional in the Targaryen family. Upon the streets learning of Viserys' passing, a coronation ceremony was held where the greens crowned Aegon as the new Lord of the Seven Kingdoms. Aegon's claim was rejected by a furious Rhaenyra, who had a coronation of her own set up by Daemon and the blacks. The coming struggle for power between Aegon and Rhaenyra came to be known as the Dance of the Dragons, a civil war between the greens and blacks.
==== Historical funding ==== Over the last century, the responsibility to allocate funding has shifted from the OD and Advisory Committee to the individual ICs and Congress increasingly set apart funding for particular causes. In the 1970s, Congress began to earmark funds specifically for cancer research, and in the 1980s there was a significant amount allocated for AIDS/HIV research. Funding for the NIH has often been a source of contention in Congress, serving as a proxy for the political currents of the time. During the 1980s, President Reagan repeatedly tried to cut funding for research, only to see Congress partly restore funding. The political contention over NIH funding slowed the nation's response to the AIDS epidemic; while AIDS was reported in newspaper articles from 1981, no funding was provided for research on the disease. In 1984 National Cancer Institute scientists found implications that "variants of a human cancer virus called HTLV-III are the primary cause of acquired immunodeficiency syndrome (AIDS)," a new epidemic that gripped the nation. In 1992, the NIH encompassed nearly 1 percent of the federal government's operating budget and controlled more than 50 percent of all funding for health research and 85 percent of all funding for health studies in universities. From 1993 to 2001 the NIH budget doubled. For a time, funding essentially remained flat, and for seven years after the 2008 financial crisis, the NIH budget struggled to keep up with inflation. In 1999 Congress increased the NIH's budget by $2.3 billion to $17.2 billion in 2000.
== Adverse effects == The safety profile of oliceridine is similar to other opioids. As with other opioids, the most common side effects of oliceridine are nausea, vomiting, dizziness, headache and constipation. Prolonged use of opioid analgesics during pregnancy can result in neonatal opioid withdrawal syndrome. Olinvyk carries a boxed warning about addiction, abuse and misuse; life-threatening respiratory depression; neonatal opioid withdrawal syndrome; and risks from concomitant use with benzodiazepines or other central nervous system depressants. Unlike other opioids for intravenous administration, Olinvyk has a maximum recommended daily dose limit of 27 milligrams.
Sources: en.wikipedia.org
=== Competitive === The binding of oxygen is affected by molecules such as carbon monoxide (for example, from tobacco smoking, exhaust gas, and incomplete combustion in furnaces). CO competes with oxygen at the heme binding site. Hemoglobin's binding affinity for CO is 250 times greater than its affinity for oxygen. Since carbon monoxide is a colorless, odorless, and tasteless gas, and poses a potentially fatal threat, carbon monoxide detectors have become commercially available to warn of dangerous levels in residences. When hemoglobin combines with CO, it forms a very bright red compound called carboxyhemoglobin, which may cause the skin of CO poisoning victims to appear pink in death, instead of white or blue. When inspired air contains CO levels as low as 0.02%, headache and nausea occur; if the CO concentration is increased to 0.1%, unconsciousness will follow. In heavy smokers, up to 20% of the oxygen-active sites can be blocked by CO. In similar fashion, hemoglobin also has competitive binding affinity for cyanide (CN−), sulfur monoxide (SO), and sulfide (S2−), including hydrogen sulfide (H2S). All of these bind to iron in heme without changing its oxidation state, but they nevertheless inhibit oxygen-binding, causing grave toxicity. The iron atom in the heme group must initially be in the ferrous (Fe2+) oxidation state to support oxygen and other gases' binding and transport (it temporarily switches to ferric during the time oxygen is bound, as explained above).
Furthermore, various formal and legal issues were found in multiple restaurants, such as dirty waste buckets too close to fresh food, parts of operations done under the company ID of the parent company instead of the actual restaurant as registered with food safety authorities, and incomplete paperwork on deliveries. In September 2025, Czech journalist Jan Tuna reported that the practices of artificially extending the shelf life of meat that led to the closure of all KFC outlets in Denmark may also be used by some branches in the Czech Republic. He cited the testimony of a former employee from the Jablonec nad Nisou branch. The State Agricultural and Food Inspection Authority later revealed that similar practices were used by the KFC outlet in Liberec. The inspection subsequently decided to carry out mass inspections of KFC restaurants throughout the country. In November the spokesperson of the State Agricultural and Food Inspection Authority revealed that employees of the KFC outlet in Prague-Dejvice defrosted chicken meat in standing water, which increases microbiological risks.
== External links == Overview of all the structural information available in the PDB for UniProt: P05305 (Endothelin-1) at the PDBe-KB. This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.